Robert W. Carlson
Academic Appointments
- Emeritus Faculty-Med Ctr Line, Medicine - Oncology
- Member, Stanford Cancer Institute
Key Documents
Contact Information
- Academic Offices
Personal Information Email
Professional Overview
Administrative Appointments
- Chair, Scientific Review Committee, Stanford Cancer Institute (2009 - present)
- Unit-based Medical Director, F-Ground, Stanford Hospital and Clinics (2009 - present)
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industrial and other commercial partners. It is our policy to disclose payments (exclusive of travel support) from, and/or equity in, companies or other commercial entities to Stanford faculty of $5,000 or more in total value, as well as any equity in a privately held company, when the faculty member also has institutional responsibilities related to his or her interactions with the company. View Full Information
Scientific Focus
Current Research Interests
Clinical investigations in breast cancer include institutional and NSABP studies of chemoprevention, adjuvant therapy, psychosocial interventions, treatment of metastatic disease, methods of decreasing anthracycline cardiotoxicity, and modulation of multidrug resistance. Research in meta-analysis includes the performance of meta-analysis in a wide variety of settings in cancer treatment by the international Meta-Analysis Group in Cancer.
Computer science research efforts focus on computer-based systems for patient care. These include: the development of expert systems to assist in the care of patients with cancer (ONCOCIN) or AIDS (T-Helper); the development of computer-based systems using speech and pen-based input for medical records to access sources of medical knowledge; the design of three-dimensional methods of performing and representing literature searches; and the development of standards for implementing of medical computer-based systems; the development of smart agents and medical ontologies.
Clinical Trials
- Not Recruiting Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
- Not Recruiting Radiation Therapy in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer
- Recruiting Intellectual Impairment in Women With Breast Cancer
- Not Recruiting A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy
- Recruiting Vitamin D and Breast Cancer: Does Weight Make a Difference?
Publications
- mTOR inhibitors in the treatment of breast cancer. Oncology (Williston Park). 2013; (1): 38-44, 46, 48 passim
- Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS One. 2012; (5): e33788
- Invasive breast cancer. J Natl Compr Canc Netw. 2011; (2): 136-222
- Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally? J Am Coll Cardiol. 2010; (20): 1644-50
- Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women. J Clin Oncol. 2010; (25): 3917-21
- First-line chemotherapy for metastatic breast cancer. Clin Breast Cancer. 2009: S66-72
Help
Trial Administration